JPRN-jRCTs031230063进行中（未招募）4 期
The efficacy of delgocitinib ointment for treating skin rashes on the face or neck in patients with atopic dermatitis.The effect of topical steroids or tacrolimus ointment in reducing local side effects.
Masatoshi Abe0 个研究点目标入组 40 人开始时间: 2023年5月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients aged 18 years and older with atopic dermatitis when obtaining consent.
- •(2) Patients using topical steroids or tacrolimus ointment* for face or neck rash for more than 3 months.
- •(3) Patients with local side effects such as skin atrophy, vasodilation, or rosacea-like dermatitis as a result of treatment with topical steroids or who are expected to use topical steroids for a long time and are concerned about the development of local side effects or patients with local side effects such as skin irritation, or rosacea-like dermatitis due to the use of tacrolimus ointment on the face or neck.
- •(4) Patients who have given written consent to participate in the study.
- •**: Any rank and formulation of topical steroids.
- •**: Any concentration of tacrolimus ointment.
排除标准
- •(1) Patients using the strongest topical steroids on the face or neck.
- •(2) Patients using delgocitinib ointment on the face or neck.
- •(3) Patients using difamilast ointment.
- •(4) Patients with plaque or other erosions forming obvious foci at the observation site.
- •(5) Patients who are pregnant, may become pregnant, or plan to become pregnant during the study period.
- •(6) Patients who are breastfeeding
- •(7) Patients previously treated with delgocitinib ointment
- •(8) Patients receiving systemic therapy with internal medications (steroids, cyclosporine, JAK inhibitors) at the time consent was obtained or within the last 3 months.
- •(9) Patients receiving systemic therapy with biologics (e.g., dupilumab, nemolizumab) at the time consent was obtained or within the last 6 months
- •(10) Patients receiving phototherapy, such as ultraviolet light therapy, at the time consent was obtained or within the last 3 months.
- •(11) Patients who have participated in a clinical trial or similar within the last 6 months
- •(12) Patients deemed ineligible for the study by the investigator or others.
研究者
相似试验
招募中
Unknown
Clinical Effects of Delgocitinib Ointment on Skin Barrier Dysfunction in Pediatric Atopic DermatitisAtopic DermatitisJPRN-UMIN000049841ational Hospital Organization Sagamihara National Hospital70
进行中（未招募）
1 期
Efficacy of Nintedanib per os as a treatment for epistaxis in HHT diseaseEPICUREHereditary Hemorrhagic TelangiectasiaMedDRA version: 20.1Level: LLTClassification code 10019887Term: Hereditary hemorrhagic telangiectasiaSystem Organ Class: 100000004850EUCTR2019-002593-31-FRHospices Civils de Lyon60
已完成
2 期
Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.cutaneous cGVHD.Graft-versus-host reaction or diseaseIRCT201302261030N12Hematology-Oncology and SCT Research Center28
已完成
3 期
Effect of hydroalcoholic extract of Ruscus hyrcanus in treatment of chronic venous insufficiencyIRCT20100107003014N20Vice chancellor for research and technology, Mazandaran University of Medical Sciences60
招募中
早期 1 期
Effect of hydroalcoholic extract of Ruscus hyrcanus in treatment of chronic venous insufficiencyIRCT20100107003014N21Sari University of Medical Sciences60